Objective: To investigate the significance of the differential expression of annexin A3 (ANX A3) in osteosarcoma tissues and cells. Methods: The expression of ANX A3 in osteosarcoma tissues and adjacent tissues was analyzed by immunohistochemistry, and the expression of ANX A3 in human osteosarcoma cell lines, osteoblast cell lines, ANX A3 overexpression or knockdown osteosarcoma cell lines was detected by Western blot. Scratch test and cell counting kit-8 were used to analyze the invasion and proliferation of ANX A3 overexpression or knockdown osteosarcoma cell lines. Results: The positive rate of ANX A3 expression in osteosarcoma tissues was significantly higher than that in adjacent tissues, and the difference was statistically significant(P＜0.05). The positive rate of ANX A3 expression in pathological tissues of patients with distant metastasis was significantly higher than that of patients without distant metastasis, the difference was statistically significant (P＜0.05). The expression level of ANX A3 in human osteosarcoma cell line was 2.96 times higher than that in osteoblast cell line, the difference was statistically significant(P＜0.05). Compared with osteoblast cell lines, the level of ANX A3 in overexpressing cell lines was significantly up-regulated by about 3.52 times, while that in knockout cell lines was significantly down-regulated,and the difference was statistically significant(P＜0.05).The migration and proliferation ability of ANX A3 overexpression strain was significantly higher than that of knockdown strain, the difference was statistically significant(P＜0.05). Conclusions: Compared with adjacent tissues, ANX A3 is significantly expressed in osteosarcoma tissues, and the positive rate of ANX A3 is higher in pathological tissues of patients with distant metastasis. ANX A3 may promote the proliferation and migration of osteosarcoma, and may become a potential target for the treatment of osteosarcoma.
ZHENG Jialei
,
MO Huanhuan
,
ZHAO Yan
,
HU Ting
. Expression and significance of annexin A3 in osteosarcoma[J]. Journal of Baotou Medical College, 2025
, 41(2)
: 29
-34
.
DOI: 10.16833/j.cnki.jbmc.2025.02.006
[1] Gill J, Gorlick R. Advancing therapy for osteosarcoma[J]. Nat Rev Clin Oncol, 2021, 18(10): 609-624.
[2] 郑家雷, 莫缓缓, 吴骁, 等. 大剂量甲氨蝶呤、表柔比星联合顺铂新辅助化疗骨肉瘤的疗效分析[J]. 包头医学院学报, 2022, 38(9): 10-14.
[3] Meltzer PS, Helman J. New horizons in the treatment of osteosarcoma[J]. N Engl J Med, 2021, 385(22): 2066-2076.
[4] Smrke A, Anderson PM, Gulia A, et al. Future directions in the treatment of osteosarcoma[J]. Cells, 2021, 10(1): 172.
[5] Jafari F, Javdansirat S, Sanaie S, et al. Osteosarcoma: a comprehensive review of management and treatment strategies[J]. Ann Diagn Pathol, 2020, 49: 151654.
[6] Zhao X, Wu QR, Gong XQ, et al. Osteosarcoma: a review of current and future therapeutic approaches[J]. Biomed Eng Online, 2021, 20(1): 24.
[7] Chen SJ, Zeng J, Huang LP, et al. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma[J]. J Transl Med, 2022, 20(1): 228.
[8] Schloer S, Pajonczyk D, Rescher U. Annexins in translational research: hidden treasures to be found[J]. Int J Mol Sci, 2018, 19(6): 1781.
[9] 马聪聪, 陆红祥, 史清海. 膜联蛋白A3在相关疾病诊疗中的研究进展[J]. 新疆医学, 2022, 52(6): 628-631, 638.
[10] 朱利芹, 宗明珠, 杜楠. 外周血及肿瘤组织中膜联蛋白A3、缺氧诱导因子-1α表达对结直肠癌铂类耐药的预测价值[J]. 癌症进展, 2021, 19(22): 2303-2306.
[11] Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma[J]. Nat Rev Dis Primers, 2022, 8: 77.
[12] Xu HR, Huang Z, Li Y, et al. Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study[J].Cancer Biol Med, 2019, 16(1): 166-172.
[13] Mussunoor S, Murray GI. The role of annexins in tumour development and progression[J]. J Pathol, 2008, 216(2): 131-140.
[14] Gao SH, Wang ZZ, Liu XZ, et al. The calcimedin annexin A3 displays tumor-promoting effect in esophageal squamous cell carcinoma by activating NF-κB signaling[J]. Mamm Genome, 2021, 32(5): 381-388.
[15] Wan XH, Guo DR, Zhu Q, et al. MicroRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(3): G309-G322.
[16] Wozny W, Schroer K, Schwall GP, et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3[J].Proteomics, 2007, 7(2): 313-322.
[17] Ma XL, Jiang M, Zhao Y, et al. Application of serum annexin A3 in diagnosis, outcome prediction and therapeutic response evaluation for patients with hepatocellular carcinoma[J].Ann Surg Oncol, 2018, 25(6): 1686-1694.
[18] Zhu Q, Pan QZ, Zhong AL, et al. Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma[J].Int Immunopharmacol, 2020, 89: 107139.
[19] Wang ST, Zeng XX, Gui P, et al. LncRNA EBLN3P facilitates osteosarcoma metastasis by enhancing annexin A3 mRNA stability and recruiting HuR[J].AnnSurgoncol, 2023, 30(13): 8690-8703.
[20] Wang J, Jia X, Meng XX, et al. Annexin A3 may play an important role in ochratoxin-induced malignant transformation of human gastric epithelium cells[J].Toxicol Lett, 2019, 313: 150-158.
